AVIR Stock Summary and Trading Ideas (Atea Pharmaceuticals | NASDAQ:AVIR)

Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

Atea Pharmaceuticals trades on the NASDAQ stock market under the symbol AVIR.

As of April 8, 2026, AVIR stock price declined to $5.95 with 274,925 million shares trading.

AVIR has a beta of 0.36, meaning it tends to be less sensitive to market movements. AVIR has a correlation of 0.01 to the broad based SPY ETF.

AVIR has a market cap of $474.05 million. This is considered a Small Cap stock.

In the last 3 years, AVIR traded as high as $6.45 and as low as $2.46.

The top ETF exchange traded funds that AVIR belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

AVIR has outperformed the market in the last year with a price return of +114.0% while the SPY ETF gained +35.3%. AVIR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +71.0% and +11.6%, respectively, while the SPY returned -1.8% and +3.4%, respectively.

AVIR support price is $5.76 and resistance is $6.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVIR shares will trade within this expected range on the day.